Presentation of the Centre
INOC – Istituto Nazionale Oncologico Candiolo is a leading center for advanced diagnostics,
treatment and research of oncological and haematological diseases. Established in 1996, it was
designated in 2013 as an Institute for Research and Healthcare (IRCCS) by the Italian Ministry of
Health, the first and only such institute in Piedmont. The Institute's mission is built on the principle
that research drives care and care inspires research: clinical practice and scientific research
work in close synergy, through a multidisciplinary approach and consolidated collaboration between
specialist teams and research units, to ensure the rapid translation of scientific discoveries into
personalized, effective treatment for patients. Each year the Institute cares for over 37,000 patients.
Main Research Activities
The Institute's research spans:
(i) basic, translational and clinical cancer research, including participation in national and
international clinical trials (investigator initiated and industry-sponsored clinical trials phase I–IV),
giving patients early access to innovative therapies;
(ii) rapid translation of research findings into clinical practice;
(iii) development and adoption of cutting-edge diagnostic and therapeutic technologies; and
(iv) early diagnosis and cancer prevention through the study of genetic and environmental risk factors.
A key emerging platform is BioLife, an integrated translational research infrastructure
being developed around the Institute's oncology biobank, intended to become the largest of its kind
in Italy.
The Institute is also equipped with state-of-the-art technology platforms in diagnostic imaging,
robotic and minimally invasive surgery, precision radiotherapy, and high-throughput molecular
pathology (including next-generation sequencing for comprehensive genomic profiling).
Research Laboratories
The Institute hosts 18 active research laboratories, involving nearly 300 Italian and international
researchers, including:
- Oncogenomics
- Translational Cancer Genetics
- Cancer Molecular Biology
- Cancer Stem Cell Research
- Cell Adhesion Dynamics
- Tumor Microenvironment / Vascular Oncology
- Experimental Molecular Pathology
- Translational Cancer Medicine
- Cancer Immunotherapy
- Clinical Research Unit (CRU) / Phase I Clinical Unit
Recognition and Networks
Since 2008 the Institute has been part of the Piedmont and Aosta Valley Oncology Network, joined
the National Research Cancer Network - Alliance Against Cancer (ACC) in 2016, and in May 2022
was accredited by the Organisation of European Cancer Institutes (OECI) as a
Comprehensive Cancer Centre, OECI's highest designation. It is actively involved in the
European Joint Action-EUNetCCC (European Network of Comprehensive Cancer Centres).
Education
The Institute maintains a close partnership with the University of Turin, strengthening its combined
research and teaching mission: researchers, physicians and students collaborate on joint projects,
and the Institute hosts numerous University medical faculty professionals. It also partners with the
Italian Institute for Genomic Medicine (IIGM) to integrate advanced genomic research into patient care.